Cargando…
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
BACKGROUND: This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice. METHODS: The clinical data of patients with ER+ metastatic breast can...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509029/ https://www.ncbi.nlm.nih.gov/pubmed/35984107 http://dx.doi.org/10.1097/CM9.0000000000002240 |
_version_ | 1784797146338295808 |
---|---|
author | Mo, Hongnan Ma, Fei Li, Qing Zhang, Pin Yuan, Peng Wang, Jiayu Luo, Yang Cai, Ruigang Li, Qiao Xu, Binghe |
author_facet | Mo, Hongnan Ma, Fei Li, Qing Zhang, Pin Yuan, Peng Wang, Jiayu Luo, Yang Cai, Ruigang Li, Qiao Xu, Binghe |
author_sort | Mo, Hongnan |
collection | PubMed |
description | BACKGROUND: This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice. METHODS: The clinical data of patients with ER+ metastatic breast cancer treated with palbociclib were collected from the National Cancer Center database. The efficacy profile of palbociclib in this Han population was evaluated, especially for various combination regimens. The efficacy of palbociclib-based therapy in patients with prior everolimus treatment was also assessed. RESULTS: A total of 186 patients from 89 cities in 18 provinces in China were enrolled. The median progression-free survival (PFS) was similar among different palbociclib-combined groups (P = 0.566): 10.0 months (95% confidence interval [CI] 3.8–16.1) in the +exemestane group, 9.7 months (95% CI 6.3–13.1) in the +letrozole group, 7.8 months (95% CI 5.5–10.2) in the +fulvestrant group, 7.2 months (95% CI 3.2–11.3) in the +toremifene group, and 6.1 months (95% CI 1.2–11.0) in the +anastrozole group. Thirty-four patients (18.3%) had received everolimus for their metastatic disease before the prescription of palbociclib. The disease control rate was significantly lower in patients who had received previous everolimus than in the everolimus-naïve group (50.0% vs. 82.2%, P < 0.001). Patients pre-treated with everolimus had significantly worse PFS than those in the everolimus-naïve group (3.4 months vs. 8.8 months, P = 0.001). After propensity score matching, patients pre-treated with everolimus had similar PFS (4.4 months, 95% CI 0.5–8.2) compared with everolimus-naïve patients (6.1 months, 95% CI 4.7–7.5, P = 0.439). CONCLUSIONS: Various palbociclib-based regimens have promising efficacy in ER+ metastatic breast cancer in real-world settings, even in patients who had been pre-treated with everolimus. |
format | Online Article Text |
id | pubmed-9509029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95090292022-09-26 Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population Mo, Hongnan Ma, Fei Li, Qing Zhang, Pin Yuan, Peng Wang, Jiayu Luo, Yang Cai, Ruigang Li, Qiao Xu, Binghe Chin Med J (Engl) Original Articles BACKGROUND: This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice. METHODS: The clinical data of patients with ER+ metastatic breast cancer treated with palbociclib were collected from the National Cancer Center database. The efficacy profile of palbociclib in this Han population was evaluated, especially for various combination regimens. The efficacy of palbociclib-based therapy in patients with prior everolimus treatment was also assessed. RESULTS: A total of 186 patients from 89 cities in 18 provinces in China were enrolled. The median progression-free survival (PFS) was similar among different palbociclib-combined groups (P = 0.566): 10.0 months (95% confidence interval [CI] 3.8–16.1) in the +exemestane group, 9.7 months (95% CI 6.3–13.1) in the +letrozole group, 7.8 months (95% CI 5.5–10.2) in the +fulvestrant group, 7.2 months (95% CI 3.2–11.3) in the +toremifene group, and 6.1 months (95% CI 1.2–11.0) in the +anastrozole group. Thirty-four patients (18.3%) had received everolimus for their metastatic disease before the prescription of palbociclib. The disease control rate was significantly lower in patients who had received previous everolimus than in the everolimus-naïve group (50.0% vs. 82.2%, P < 0.001). Patients pre-treated with everolimus had significantly worse PFS than those in the everolimus-naïve group (3.4 months vs. 8.8 months, P = 0.001). After propensity score matching, patients pre-treated with everolimus had similar PFS (4.4 months, 95% CI 0.5–8.2) compared with everolimus-naïve patients (6.1 months, 95% CI 4.7–7.5, P = 0.439). CONCLUSIONS: Various palbociclib-based regimens have promising efficacy in ER+ metastatic breast cancer in real-world settings, even in patients who had been pre-treated with everolimus. Lippincott Williams & Wilkins 2022-07-20 2022-08-18 /pmc/articles/PMC9509029/ /pubmed/35984107 http://dx.doi.org/10.1097/CM9.0000000000002240 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Articles Mo, Hongnan Ma, Fei Li, Qing Zhang, Pin Yuan, Peng Wang, Jiayu Luo, Yang Cai, Ruigang Li, Qiao Xu, Binghe Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title_full | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title_fullStr | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title_full_unstemmed | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title_short | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population |
title_sort | treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the han population |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509029/ https://www.ncbi.nlm.nih.gov/pubmed/35984107 http://dx.doi.org/10.1097/CM9.0000000000002240 |
work_keys_str_mv | AT mohongnan treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT mafei treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT liqing treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT zhangpin treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT yuanpeng treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT wangjiayu treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT luoyang treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT cairuigang treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT liqiao treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation AT xubinghe treatmentpatternsandclinicaloutcomesinpatientswithmetastaticbreastcancertreatedwithpalbociclibbasedtherapiesrealworlddatainthehanpopulation |